Pub Date : 2015-10-10DOI: 10.17554/J.ISSN.2309-6861.2015.02.94
A. Berezin
Type 2 diabetes mellitus (T2DM) is one of the most prevalent metabolic diseases that associated with increased risk for cardiovascular (CV) diseases and newly CV events. Although CV risk assessment is incorporated in primary and secondary prevention strategies to improve morbidity and mortality that are applied in diabetic patient, it is important to stratify individuals at high CV risk not just prior diabetic complication, but at early stages of development of the CV diseases. The aim of the editorial comment is to discuss possible predictive role of cardiac biomarkers in T2DM. Cardiac biomarkers may contribute to improved prediction of CV mortality and CAD incidences in T2DM. It has suggested that measurement of serum levels of hs-CRP, galectin-3, NPs, and hs-cTnT probably allows the identification of T2DM patients the most at risk of CV events. Future directions are associated with discovering of novel biomarkers and optimal combinations of recently used markers to provide additional prognostic information beyond what is available with other traditional CV risk factors.
{"title":"The Role of Cardiac Biomarkers in Predicting of Mortality in Diabetic Patients","authors":"A. Berezin","doi":"10.17554/J.ISSN.2309-6861.2015.02.94","DOIUrl":"https://doi.org/10.17554/J.ISSN.2309-6861.2015.02.94","url":null,"abstract":"Type 2 diabetes mellitus (T2DM) is one of the most prevalent metabolic diseases that associated with increased risk for cardiovascular (CV) diseases and newly CV events. Although CV risk assessment is incorporated in primary and secondary prevention strategies to improve morbidity and mortality that are applied in diabetic patient, it is important to stratify individuals at high CV risk not just prior diabetic complication, but at early stages of development of the CV diseases. The aim of the editorial comment is to discuss possible predictive role of cardiac biomarkers in T2DM. Cardiac biomarkers may contribute to improved prediction of CV mortality and CAD incidences in T2DM. It has suggested that measurement of serum levels of hs-CRP, galectin-3, NPs, and hs-cTnT probably allows the identification of T2DM patients the most at risk of CV events. Future directions are associated with discovering of novel biomarkers and optimal combinations of recently used markers to provide additional prognostic information beyond what is available with other traditional CV risk factors.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"28 1","pages":"400-404"},"PeriodicalIF":0.0,"publicationDate":"2015-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91379806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-10-10DOI: 10.17554/j.issn.2309-6861.2015.02.92
W. Aronow
Patients with coronary artery disease should have intensive treatment of modifiable coronary risk factors. Dietary sodium should be decreased. Hypertension should be treated with beta blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Long-acting nitrates are effective antianginal and antiischemic medications. Calcium channel blockers may be added if angina pectoris persists despite beta blockers and long-acting nitrates. The American Heart Association/American Society of Cardiology 2015 guidelines recommend a target blood pressure below 140/90 mm Hg in patients with coronary artery disease and with an acute coronary syndrome if they are aged 80 years and younger but below 150 mm Hg if they are ≥80 years of age. Octogenarians should be checked for orthostatic changes with standing, and a a systolic blood pressure below 130 mm Hg and a diastolic blood pressure below 65 mm Hg must be avoided. Caution is advised in lowering the diastolic blood pressure below 60 mm Hg in diabetics or in patients older than 60 years of age. In addition to the beta blockers carvedilol, metoprolol CR/XL, and bisoprolol, patients with hypertension and heart failure should be treated with diuretics and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and patients with persistent severe symptoms with aldosterone antagonists if not contraindicated.
{"title":"2015 Guidelines on Treatment of Hypertension in Patients With Coronary Artery Disease","authors":"W. Aronow","doi":"10.17554/j.issn.2309-6861.2015.02.92","DOIUrl":"https://doi.org/10.17554/j.issn.2309-6861.2015.02.92","url":null,"abstract":"Patients with coronary artery disease should have intensive treatment of modifiable coronary risk factors. Dietary sodium should be decreased. Hypertension should be treated with beta blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Long-acting nitrates are effective antianginal and antiischemic medications. Calcium channel blockers may be added if angina pectoris persists despite beta blockers and long-acting nitrates. The American Heart Association/American Society of Cardiology 2015 guidelines recommend a target blood pressure below 140/90 mm Hg in patients with coronary artery disease and with an acute coronary syndrome if they are aged 80 years and younger but below 150 mm Hg if they are ≥80 years of age. Octogenarians should be checked for orthostatic changes with standing, and a a systolic blood pressure below 130 mm Hg and a diastolic blood pressure below 65 mm Hg must be avoided. Caution is advised in lowering the diastolic blood pressure below 60 mm Hg in diabetics or in patients older than 60 years of age. In addition to the beta blockers carvedilol, metoprolol CR/XL, and bisoprolol, patients with hypertension and heart failure should be treated with diuretics and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and patients with persistent severe symptoms with aldosterone antagonists if not contraindicated.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"3 1","pages":"418-421"},"PeriodicalIF":0.0,"publicationDate":"2015-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79344050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-10-10DOI: 10.17554/j.issn.2309-6861.2015.02.88
C. Rostagno
Although surgery for fractured neck of femur is the highest risk among commonly performed surgery in medicine, there are very few data investigating treatment strategies to reduce the risk in this elderly and frail group of patients. Bedside echocardiography may be an useful tool to stratify surgical risk and optimize anesthesiology strategy. Echocardiography may help to assess a patient's intravascular volume status, myocardial contractility/ventricular ejection fraction and valvular heart disease in the peri-operative period. Careful patient selection based on multidisciplinary approach for pre-operative echocardiography is important to avoid unnecessary delay to surgery and at the same time to manage high risk conditions that may negatively affect the outcome of hip surgery. Larger studies are needed to establish the cost effectiveness of such approach.
{"title":"Bedside Echocardiography In Patients With Hip Fracture","authors":"C. Rostagno","doi":"10.17554/j.issn.2309-6861.2015.02.88","DOIUrl":"https://doi.org/10.17554/j.issn.2309-6861.2015.02.88","url":null,"abstract":"Although surgery for fractured neck of femur is the highest risk among commonly performed surgery in medicine, there are very few data investigating treatment strategies to reduce the risk in this elderly and frail group of patients. Bedside echocardiography may be an useful tool to stratify surgical risk and optimize anesthesiology strategy. Echocardiography may help to assess a patient's intravascular volume status, myocardial contractility/ventricular ejection fraction and valvular heart disease in the peri-operative period. Careful patient selection based on multidisciplinary approach for pre-operative echocardiography is important to avoid unnecessary delay to surgery and at the same time to manage high risk conditions that may negatively affect the outcome of hip surgery. Larger studies are needed to establish the cost effectiveness of such approach.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"50 1","pages":"410-413"},"PeriodicalIF":0.0,"publicationDate":"2015-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85064896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-10-10DOI: 10.17554/j.issn.2309-6861.2015.02.93
R. Singh, K. Hristova, J. Fedacko, G. Elkilany, N. Verma
Evolocumab, alirocumab and bococizumab are leading monoclonal antibodies that are called Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. These agents have been used in multicenter studies to demonstrate their efficacy and safety and effect on blood lipoproteins as well as on cardiovascular outcomes indicating significant beneficial effects without much adverse effects.
Evolocumab、alirocumab和bococizumab是领先的单克隆抗体，被称为Proprotein convertase subtilisin/ keexin type 9 (PCSK9)抑制剂。这些药物已在多中心研究中使用，以证明其有效性和安全性，以及对血脂和心血管结局的影响，表明显着的有益效果而没有太多的不良反应。
{"title":"New Clinical Trials With Evolocumab and Alirocumab on Cardiovascular Outcomes, in Patients With High Rsk of Acute Coronary Syndromes","authors":"R. Singh, K. Hristova, J. Fedacko, G. Elkilany, N. Verma","doi":"10.17554/j.issn.2309-6861.2015.02.93","DOIUrl":"https://doi.org/10.17554/j.issn.2309-6861.2015.02.93","url":null,"abstract":"Evolocumab, alirocumab and bococizumab are leading monoclonal antibodies that are called Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. These agents have been used in multicenter studies to demonstrate their efficacy and safety and effect on blood lipoproteins as well as on cardiovascular outcomes indicating significant beneficial effects without much adverse effects.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"1 1","pages":"422-424"},"PeriodicalIF":0.0,"publicationDate":"2015-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88562306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-10-10DOI: 10.17554/j.issn.2309-6861.2015.02.79
Bo Xu, V. Nadurata, K. Avery, C. Chilvers, Shelene Laiu
Background: Primary percutaneous coronary intervention (PCI) is the standard of care for ST-elevation myocardial infarction (STEMI). In rural and remote centres with limited facilities, a pharmaco-invasive approach with thrombolysis followed by transfer of patients to PCI-capable centres remains important. Contemporary Australian data regarding pharmaco-invasive STEMI management are lacking. The primary objective of this study was to examine the clinical outcomes of pharmaco-invasive STEMI management in Bendigo, a large Australian regional centre. Methods: A retrospective analysis was performed for all patients presenting to Bendigo Health with an admission diagnosis of STEMI in the emergency department, between February 2013 and January 2014. During the study period, 68 consecutive patients received an admission diagnosis of STEMI in the emergency department. Of these, 58 patients were actually diagnosed with STEMI due to obstructive coronary artery disease, and received thrombolysis. These patients were divided into two groups: (1) Pharmaco-invasive local (Local) group: thrombolysis with subsequent coronary angiography locally in Bendigo; (2) Pharmaco-invasive transfer (Transfer) group: thrombolysis with immediate transfer for coronary angiography. Door-to-Needle time (DTN), Thrombolysis-to-Angiography time (TTA), transfer cost, and inpatient morbidity and mortality were collected. Results: DTN was more prolonged in the Local group (38 ± 35 minutes versus 25 ± 23 minutes, p=0.135). DTN 24 hours for angiography, and a significantly higher proportion of patients being managed by surgery and medical therapy. In a contemporary regional Australian pharmaco-invasive STEMI cohort, significant opportunities existed to improve patient outcomes.
背景:初级经皮冠状动脉介入治疗(PCI)是st段抬高型心肌梗死(STEMI)的标准治疗方法。在设施有限的农村和偏远中心，采用药物侵入性溶栓方法，然后将患者转移到有pci能力的中心仍然很重要。当代澳大利亚缺乏关于药物侵入性STEMI管理的数据。本研究的主要目的是检查澳大利亚大型区域中心Bendigo药物侵入性STEMI管理的临床结果。方法:回顾性分析2013年2月至2014年1月在本迪戈健康中心急诊就诊并被诊断为STEMI的所有患者。在研究期间，68例连续患者在急诊科接受STEMI的入院诊断。其中，58例患者被诊断为阻塞性冠状动脉疾病导致的STEMI，并接受了溶栓治疗。这些患者分为两组:(1)药物侵入局部(local)组:溶栓并在Bendigo局部冠状动脉造影;(2)药物有创转移(transfer)组:溶栓立即转移冠状动脉造影。收集门到针时间(DTN)、溶栓到血管造影时间(TTA)、转移费用、住院发病率和死亡率。结果:Local组DTN延长(38±35 min vs 25±23 min, p=0.135)。DTN 24小时进行血管造影，通过手术和药物治疗的患者比例明显更高。在当代澳大利亚区域性药物侵入性STEMI队列中，存在显著改善患者预后的机会。
{"title":"Clinical Outcomes of Pharmaco-invasive ST-elevation Myocardial Infarction Management in a Large Australian Regional Centre","authors":"Bo Xu, V. Nadurata, K. Avery, C. Chilvers, Shelene Laiu","doi":"10.17554/j.issn.2309-6861.2015.02.79","DOIUrl":"https://doi.org/10.17554/j.issn.2309-6861.2015.02.79","url":null,"abstract":"Background: Primary percutaneous coronary intervention (PCI) is the standard of care for ST-elevation myocardial infarction (STEMI). In rural and remote centres with limited facilities, a pharmaco-invasive approach with thrombolysis followed by transfer of patients to PCI-capable centres remains important. Contemporary Australian data regarding pharmaco-invasive STEMI management are lacking. The primary objective of this study was to examine the clinical outcomes of pharmaco-invasive STEMI management in Bendigo, a large Australian regional centre. Methods: A retrospective analysis was performed for all patients presenting to Bendigo Health with an admission diagnosis of STEMI in the emergency department, between February 2013 and January 2014. During the study period, 68 consecutive patients received an admission diagnosis of STEMI in the emergency department. Of these, 58 patients were actually diagnosed with STEMI due to obstructive coronary artery disease, and received thrombolysis. These patients were divided into two groups: (1) Pharmaco-invasive local (Local) group: thrombolysis with subsequent coronary angiography locally in Bendigo; (2) Pharmaco-invasive transfer (Transfer) group: thrombolysis with immediate transfer for coronary angiography. Door-to-Needle time (DTN), Thrombolysis-to-Angiography time (TTA), transfer cost, and inpatient morbidity and mortality were collected. Results: DTN was more prolonged in the Local group (38 ± 35 minutes versus 25 ± 23 minutes, p=0.135). DTN 24 hours for angiography, and a significantly higher proportion of patients being managed by surgery and medical therapy. In a contemporary regional Australian pharmaco-invasive STEMI cohort, significant opportunities existed to improve patient outcomes.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"45 1","pages":"430-435"},"PeriodicalIF":0.0,"publicationDate":"2015-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88105099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-10-10DOI: 10.17554/j.issn.2309-6861.2015.02.90
R. Singh, B. Saboo, A. Maheshwari, Poonam Singh, N. Verma, S. Singhal, Z. P. Sharma
Poor nutrition during pregnancy may be a risk factor for low birth weight and for irreversible health issues including obesity, type 2 diabetes, hypertension and hypercholesterolemia in adult life. Low birth weight has also been related to greater mortality from coronary artery disease(CAD) and type 2 diabetes in adult life. One earlier study from Northern Europe proposed that poor social conditions in childhood may be risk factor for obesity, diabetes and cardiovascular diseases (CVDs) in later life. It is possible that multiple confounders related to energy and micronutrient deficiencies may be interacting in the process of adaptations in critical time periods, during fetal, postnatal and child development. A review of literature on the effects on birth size and length of babies and of multiple micronutrient supplementation during pregnancy in low-income countries indicates that incidence of low birth weight may be decreased by supplementation of about 15 micronutrients. This finding poses the possibility that for prevention of low birth weight, maternal micronutrient supplementation (15-20 nutrients) may be an important strategy. It is proposed that this strategy may lead the prevention of CVDs and type 2 diabetes in adult life. Cohort studies and long term follow up population based trials are needed to confirm this hypothesis.
{"title":"Can Prevention of Low Birth Weight in Newborn may be Associated with Primordial Prevention of Cardiovascular Diseases and Type 2 Diabetes in Adult Life","authors":"R. Singh, B. Saboo, A. Maheshwari, Poonam Singh, N. Verma, S. Singhal, Z. P. Sharma","doi":"10.17554/j.issn.2309-6861.2015.02.90","DOIUrl":"https://doi.org/10.17554/j.issn.2309-6861.2015.02.90","url":null,"abstract":"Poor nutrition during pregnancy may be a risk factor for low birth weight and for irreversible health issues including obesity, type 2 diabetes, hypertension and hypercholesterolemia in adult life. Low birth weight has also been related to greater mortality from coronary artery disease(CAD) and type 2 diabetes in adult life. One earlier study from Northern Europe proposed that poor social conditions in childhood may be risk factor for obesity, diabetes and cardiovascular diseases (CVDs) in later life. It is possible that multiple confounders related to energy and micronutrient deficiencies may be interacting in the process of adaptations in critical time periods, during fetal, postnatal and child development. A review of literature on the effects on birth size and length of babies and of multiple micronutrient supplementation during pregnancy in low-income countries indicates that incidence of low birth weight may be decreased by supplementation of about 15 micronutrients. This finding poses the possibility that for prevention of low birth weight, maternal micronutrient supplementation (15-20 nutrients) may be an important strategy. It is proposed that this strategy may lead the prevention of CVDs and type 2 diabetes in adult life. Cohort studies and long term follow up population based trials are needed to confirm this hypothesis.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"53 1","pages":"425-429"},"PeriodicalIF":0.0,"publicationDate":"2015-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79315289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-10-10DOI: 10.17554/j.issn.2309-6861.2015.02.91
S. Peters
There are numerous ECG features making the diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia possible such as localised right precordial QRS prolongation, right precordial QRS prolongation, terminal activation delay, S wave upstroke, epsilon waves, QRS fragmentation, reduced amplitude in precordial leads, reduced amplitude ration in right precordial leads and more than complete right bundle branch block. What is new are large Q waves, small R waves and negative T waves in lead aVR and epsilon waves in lead aVR as a risk marker of heart failure. Early repolarisation phenomen appears in 24% of cases, but it is not clear to decide, whether it is a hint of inferior aneurysm or a sign of recurrant ventricular tachycardia. Atrial fibrillation appears either early in the disease progression or very late in intensive form of the disease.
{"title":"Electrocardiographic Features in the Diagnosis and Risk Assessment of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia","authors":"S. Peters","doi":"10.17554/j.issn.2309-6861.2015.02.91","DOIUrl":"https://doi.org/10.17554/j.issn.2309-6861.2015.02.91","url":null,"abstract":"There are numerous ECG features making the diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia possible such as localised right precordial QRS prolongation, right precordial QRS prolongation, terminal activation delay, S wave upstroke, epsilon waves, QRS fragmentation, reduced amplitude in precordial leads, reduced amplitude ration in right precordial leads and more than complete right bundle branch block. What is new are large Q waves, small R waves and negative T waves in lead aVR and epsilon waves in lead aVR as a risk marker of heart failure. Early repolarisation phenomen appears in 24% of cases, but it is not clear to decide, whether it is a hint of inferior aneurysm or a sign of recurrant ventricular tachycardia. Atrial fibrillation appears either early in the disease progression or very late in intensive form of the disease.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"112 1","pages":"141-417"},"PeriodicalIF":0.0,"publicationDate":"2015-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87891314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-08-10DOI: 10.17554/j.issn.2309-6861.2015.02.84
A. Soeiro, F. Fernandes, Maria Guerreiro, Thiago Marques Mendes, M. Soeiro, T. A. Lea, D. Nakamura, F. Gaiotto, M. Oliveira
The patient is a 19-year-old male that reported a 7-year history of regular cocaine presenting at this moment with dyspnea after moderate exertion, orthopnea and paroxysmal nocturnal dyspnea for 30 days. The echocardiogram and the cardiac magnetic resonance imaging showed a giant left ventricle pseudoaneurysm secondary to the usage of cocaine and previous myocardial infarction. The combination of these situations made this patient a unique case. We showed that the surgical treatment may be an option.
{"title":"Giant Left Ventricular Pseudoaneurysm after Acute Myocardial Infarction Secondary to Cocaine Use","authors":"A. Soeiro, F. Fernandes, Maria Guerreiro, Thiago Marques Mendes, M. Soeiro, T. A. Lea, D. Nakamura, F. Gaiotto, M. Oliveira","doi":"10.17554/j.issn.2309-6861.2015.02.84","DOIUrl":"https://doi.org/10.17554/j.issn.2309-6861.2015.02.84","url":null,"abstract":"The patient is a 19-year-old male that reported a 7-year history of regular cocaine presenting at this moment with dyspnea after moderate exertion, orthopnea and paroxysmal nocturnal dyspnea for 30 days. The echocardiogram and the cardiac magnetic resonance imaging showed a giant left ventricle pseudoaneurysm secondary to the usage of cocaine and previous myocardial infarction. The combination of these situations made this patient a unique case. We showed that the surgical treatment may be an option.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"75 1","pages":"383-385"},"PeriodicalIF":0.0,"publicationDate":"2015-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85718687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-08-10DOI: 10.17554/j.issn.2309-6861.2015.02.85
Yau-Huei Lai, J. Kuo
The link between central obesity and cardiovascular diseases has been firmly established in recent years. On the other hand, numerous studies have observed that excessive body mass may be associated with a relatively favorable prognosis in advanced heart diseases. In this review article, we will summarize the findings from recent Asian and worldwide studies. We will also discuss the underlying mechanisms and other contributing factors of the obesity paradox.
{"title":"Obesity Paradox in Asian Population: the Protective Effects of Excessive Body Mass","authors":"Yau-Huei Lai, J. Kuo","doi":"10.17554/j.issn.2309-6861.2015.02.85","DOIUrl":"https://doi.org/10.17554/j.issn.2309-6861.2015.02.85","url":null,"abstract":"The link between central obesity and cardiovascular diseases has been firmly established in recent years. On the other hand, numerous studies have observed that excessive body mass may be associated with a relatively favorable prognosis in advanced heart diseases. In this review article, we will summarize the findings from recent Asian and worldwide studies. We will also discuss the underlying mechanisms and other contributing factors of the obesity paradox.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"55 1","pages":"360-364"},"PeriodicalIF":0.0,"publicationDate":"2015-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80954779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：